March 12, 2026 · BMJ (Clinical research ed.) · DOI: 10.1136/bmj-2025-086115

Camrelizumab plus CAPOX with camrelizumab based maintenance versus CAPOX alone as initial treatment for gastric or gastro-oesophageal junction adenocarcinoma: randomised phase 3 trial

Listen to this summary

This phase 3 trial aimed to compare the effectiveness of camrelizumab combined with capecitabine and oxaliplatin (CAPOX) followed by maintenance therapy with either apatinib or camrelizumab against CAPOX alone in patients with HER2-negative, unresectable gastric or gastro-oesophageal junction adenocarcinoma. The results indicated that the camrelizumab-based regimens significantly improved overall survival compared to CAPOX alone, although no additional survival benefit was observed when apatinib was added during maintenance, and higher rates of severe treatment-related adverse events were noted.

Zhi Peng, Yanqiao Zhang, Huiting Xu, Yan Yang, Mudan Yang, Mingjun Zhang, Ying Cheng, Xiaobing Chen, Yueyin Pan, Feng Wang, Qingshan Li, Nong Xu, Likun Liu, Kangsheng Gu, Juxiang Xiao, Ruixing Zhang, Qun Zhao, Jian Chen, Lizhu Lin, Yigui Chen, Yanhong Deng, Shirong Cai, Bin Bai, Yiru Wang, Lin Shen

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play